// App-Quantinova.ai

689 : Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

Researchers

Presenter

  • Betsy R. LaPlant

Principal Investigators

  • Craig Reeder

  • Garth D Nelson

  • Stephen M. Ansell

  • Thomas E. Witzig

  • James M. Foran

  • Luis F. Porrata

  • William R Macon

  • Patrick B. Johnston

  • Candido E. Rivera

  • Thomas M Habermann

  • David J. Inwards

  • Ivana N. Micallef

Medical Centers

  • Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Urinary tract infections

  • Follicular lymphoma

  • B cell lymphomas

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

  • Sepsis

  • Diffuse large B-cell lymphoma

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved